

Carsten TschÄpfe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/116713/publications.pdf>

Version: 2024-02-01

344
papers

29,914
citations

6613

79
h-index

6131

159
g-index

360
all docs

360
docs citations

360
times ranked

26102
citing authors

#	ARTICLE	IF	CITATIONS
1	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	3.3	8
2	The non-invasive assessment of myocardial work by pressure-strain analysis: clinical applications. <i>Heart Failure Reviews</i> , 2022, 27, 1261-1279.	3.9	21
3	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
4	Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CVB3-induced viral myocarditis. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 165, 31-39.	1.9	7
5	The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention. <i>Viruses</i> , 2022, 14, 299.	3.3	9
6	Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 92-101.	3.0	6
7	Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. <i>ESC Heart Failure</i> , 2022, 9, 925-941.	3.1	23
8	CMR findings after COVID-19 and after COVID-19-vaccination – same but different?. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2057-2071.	0.6	3
9	Graded lower body negative pressure induces intraventricular negative pressures and incremental diastolic suction: a pressure-volume study in a porcine model. <i>Journal of Applied Physiology</i> , 2022, 133, 20-26.	2.5	3
10	Brief Research Report: Quantitative Analysis of Potential Coronary Microvascular Disease in Suspected Long-COVID Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	11
11	Myocarditis in athletes: A clinical perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1050-1057.	1.8	37
12	Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G β oxidation. <i>Cardiovascular Research</i> , 2021, 117, 495-507.	3.8	167
13	MALDI-TOF/MS as a Tool to Determine the Myocardial Response to Syndecan-2 in Selected Mesenchymal Stromal Cell Application in an Experimental Model of Diabetic Cardiomyopathy. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000050.	1.6	8
14	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <i>Nature Reviews Cardiology</i> , 2021, 18, 169-193.	13.7	589
15	Being in Two Minds – The Challenge of Heart Failure with Preserved Ejection Fraction Diagnosis with a Single Biomarker. <i>Clinical Chemistry</i> , 2021, 67, 46-49.	3.2	1
16	Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. <i>Clinical Research in Cardiology</i> , 2021, 110, 555-568.	3.3	33
17	Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis. <i>International Journal of Cardiology</i> , 2021, 324, 131-138.	1.7	24
18	Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort. <i>Circulation</i> , 2021, 143, 289-291.	1.6	30

#	ARTICLE	IF	CITATIONS
19	COVID-19 convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture. ESC Heart Failure, 2021, 8, 971-973.	3.1	15
20	Mechanobiological Principles Influence the Immune Response in Regeneration: Implications for Bone Healing. Frontiers in Bioengineering and Biotechnology, 2021, 9, 614508.	4.1	13
21	The "TIDE" Algorithm for the Weaning of Patients With Cardiogenic Shock and Temporarily Mechanical Left Ventricular Support With Impella Devices. A Cardiovascular Physiology-Based Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 563484.	2.4	9
22	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
23	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
24	Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial. American Heart Journal, 2021, 234, 1-11.	2.7	88
25	Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis. ESC Heart Failure, 2021, 8, 2428-2437.	3.1	9
26	Myeloid-Derived Suppressor Cells Restrain Natural Killer Cell Activity in Acute Coxsackievirus B3-Induced Myocarditis. Viruses, 2021, 13, 889.	3.3	5
27	Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction: knowing more and understanding less?. European Journal of Heart Failure, 2021, 23, 964-972.	7.1	5
28	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. Frontiers in Cardiovascular Medicine, 2021, 8, 632728.	2.4	4
29	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. European Heart Journal, 2021, 42, 1940-1958.	2.2	34
30	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	7.1	105
31	Wearable cardioverter-defibrillator: friend or foe in suspected myocarditis?. ESC Heart Failure, 2021, 8, 2591-2596.	3.1	5
32	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160.	3.8	26
33	Interventricular Differences of Signaling Pathways-Mediated Regulation of Cardiomyocyte Function in Response to High Oxidative Stress in the Post-Ischemic Failing Rat Heart. Antioxidants, 2021, 10, 964.	5.1	5
34	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	1.7	29
35	Reply to "Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?". European Journal of Heart Failure, 2021, 23, 2092-2093.	7.1	0
36	Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. European Journal of Heart Failure, 2021, 23, 1891-1902.	7.1	21

#	ARTICLE	IF	CITATIONS
37	An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2483-2496.	2.1	6
38	Propensity score-based analysis of 30-day survival in cardiogenic shock patients supported with different microaxial left ventricular assist devices. <i>Journal of Cardiac Surgery</i> , 2021, 36, 4141-4152.	0.7	10
39	First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 850-855.	0.6	31
40	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e014059.	3.7	18
41	A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 75-87.	2.4	8
42	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 720690.	2.4	3
43	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 720690.	2.4	25
44	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. <i>Scientific Reports</i> , 2021, 11, 23555.	3.3	13
45	COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 737257.	2.4	33
46	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. <i>Cardiovascular Research</i> , 2020, 116, 1756-1766.	3.8	16
47	Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. <i>Heart Failure Reviews</i> , 2020, 25, 277-294.	3.9	23
48	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. <i>Clinical Research in Cardiology</i> , 2020, 109, 539-548.	3.3	2
49	Usefulness and clinical relevance of left ventricular global longitudinal systolic strain in patients with heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2020, 25, 67-73.	3.9	14
50	Coronary microvascular dysfunction in heart failure with preserved ejection fraction – adding new pieces to the jigsaw puzzle. <i>European Journal of Heart Failure</i> , 2020, 22, 442-444.	7.1	4
51	Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	7.1	24
52	Potential usefulness and clinical relevance of a novel left atrial filling index to estimate left ventricular filling pressures in patients with preserved left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 260-269.	1.2	12
53	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	2.4	34
54	Case Report First-in-Man Method Description: Left Ventricular Unloading With iVAC2L During Veno-Arterial Extracorporeal Membrane Oxygenation: From Veno-Arterial Extracorporeal Membrane Oxygenation to ECMELLA to EC-iVAC®. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 563448.	2.4	4

#	ARTICLE	IF	CITATIONS
55	Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. ESC Heart Failure, 2020, 7, 2838-2852.	3.1	13
56	Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007405.	3.9	353
57	Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. ESC Heart Failure, 2020, 7, 3531-3535.	3.1	10
58	Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 475-482.	1.1	20
59	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovascular Research, 2020, 116, 2207-2215.	3.8	189
60	Proteomic Analysis Reveals Upregulation of ACE2 (Angiotensin-Converting Enzyme 2), the Putative SARS-CoV-2 Receptor in Pressure- but Not Volume-Overloaded Human Hearts. Hypertension, 2020, 76, e41-e43.	2.7	6
61	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	4.1	12
62	<scp>SARS-CoV-2</scp>-related myocarditis-like syndromes <scp>S</scp>hakespeare's question: what's in a name?. European Journal of Heart Failure, 2020, 22, 922-925.	7.1	40
63	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
64	Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Failure, 2020, 7, 1442-1451.	3.1	26
65	Management of heart failure patients with <scp>COVID</scp>-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	7.1	95
66	Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. Frontiers in Physiology, 2020, 11, 345.	2.8	29
67	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
68	QRS fragmentation as a possible electrocardiographic diagnostic marker in patients with acute myocarditis: preliminary histopathological validation. ESC Heart Failure, 2020, 7, 2527-2533.	3.1	11
69	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
70	Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Scientific Reports, 2020, 10, 3629.	3.3	12
71	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
72	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	3.3	74

#	ARTICLE	IF	CITATIONS
73	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42
74	Case Report: Early Transplant Rejection of a Methanol-Intoxicated Donor Heart in a Young Female Patient. A Diagnostic Approach With CMR, Cardiac Biopsy, and Genetic Risk Assessment. Frontiers in Immunology, 2020, 11, 575635.	4.8	0
75	Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovascular Research, 2020, 116, 806-816.	3.8	102
76	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37
77	Patient with heart failure: importance to treat valvular diseases. European Heart Journal Supplements, 2020, 22, P38-P41.	0.1	5
78	TandemHeart pLVAD. , 2020, , 85-94.		0
79	Antiviral Therapies: A Critical Reappraisal. , 2020, , 297-316.		0
80	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. European Heart Journal, 2019, 40, 979-981.	2.2	7
81	Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. Journal of Cardiovascular Translational Research, 2019, 12, 116-123.	2.4	125
82	Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.6	32
83	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	3.7	63
84	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	3.7	27
85	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. Clinical Pharmacology and Therapeutics, 2019, 106, 1198-1208.	4.7	18
86	Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. European Journal of Heart Failure, 2019, 21, 1468-1469.	7.1	38
87	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
88	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
89	How to diagnose heart failure with preserved ejection fraction: the HFAâ€PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
90	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42

#	ARTICLE	IF	CITATIONS
91	CMR Assessment of Myocyte Disarray in HCM. Journal of the American College of Cardiology, 2019, 74, 1847-1848.	2.8	0
92	Blocking the IL-1 β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Research in Cardiology, 2019, 114, 11.	5.9	79
93	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
94	Myocardial Fibrosis Due to Exorbitant Exercise or Just Undetected Post-Inflammatory Stages?. JACC: Cardiovascular Imaging, 2019, 12, 381-382.	5.3	3
95	Management of Myocarditis-Related Cardiomyopathy in Adults. Circulation Research, 2019, 124, 1568-1583.	4.5	179
96	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	79
97	The role of fibroblast – Cardiomyocyte interaction for atrial dysfunction in HFpEF and hypertensive heart disease. Journal of Molecular and Cellular Cardiology, 2019, 131, 53-65.	1.9	15
98	Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. European Heart Journal, 2019, 40, 3318-3332.	2.2	39
99	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
100	Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. Cardiovascular Ultrasound, 2019, 17, 7.	1.6	11
101	Mode-of-action of the PROPELLA concept in fulminant myocarditis. European Heart Journal, 2019, 40, 2164-2169.	2.2	49
102	Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005250.	3.9	14
103	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Failure, 2019, 6, 146-153.	3.1	32
104	Elevated Sera sST2 Is Associated With Heart Failure in Men ≥ 50 Years Old With Myocarditis. Journal of the American Heart Association, 2019, 8, e008968.	3.7	62
105	Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. European Journal of Heart Failure, 2019, 21, 14-22.	7.1	71
106	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
107	Cardiac (myo)fibroblasts modulate the migration of monocyte subsets. Scientific Reports, 2018, 8, 5575.	3.3	26
108	Diuretic dosing in heart failure: more data are needed. ESC Heart Failure, 2018, 5, 649-650.	3.1	3

#	ARTICLE	IF	CITATIONS
109	Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2018, 217, 456-465.	4.0	10
110	Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. <i>Scientific Reports</i> , 2018, 8, 2820.	3.3	49
111	Viral myocarditis. <i>Current Opinion in Cardiology</i> , 2018, 33, 325-333.	1.8	41
112	Efficacy of RADPAD protective drape during coronary angiography. <i>Herz</i> , 2018, 43, 310-314.	1.1	15
113	The atrial appendage as a suitable source to generate cardiacâ€derived adherent proliferating cells for regenerative cellâ€based therapies. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e1404-e1417.	2.7	10
114	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239
115	Heart failure with preserved ejection fraction: current management and future strategies. <i>Clinical Research in Cardiology</i> , 2018, 107, 1-19.	3.3	64
116	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 71, 129-136.	1.9	33
117	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€terminal propeptide of procollagen type I (DROPâ€PIP trial). <i>European Journal of Heart Failure</i> , 2018, 20, 460-470.	7.1	29
118	Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 53-62.	3.1	19
119	Potential Usefulness and Clinical RelevanceÂof Adding Left Atrial Strain to LeftÂAtrialÂVolume Index in the Detection of Left Ventricular Diastolic Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1405-1415.	5.3	215
120	Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 905-915.	1.2	22
121	Repetitive levosimendan treatment in the management of advanced heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I11-I20.	0.1	23
122	Empagliflozin directly improves diastolic function in human heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1690-1700.	7.1	165
123	Long noncoding <sc>RNA</sc>s: A new player in the prevention and treatment of diabetic cardiomyopathy?. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3056.	4.0	17
124	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <i>Clinical Research in Cardiology</i> , 2018, 107, 991-1002.	3.3	37
125	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 155.	1.7	5
126	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. <i>FASEB Journal</i> , 2018, 32, 6066-6078.	0.5	42

#	ARTICLE	IF	CITATIONS
127	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
128	Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H669-H680.	3.2	6
129	Telbivudine in chronic lymphocytic myocarditis and human parvovirus <scp>B19</scp> transcriptional activity. ESC Heart Failure, 2018, 5, 818-829.	3.1	36
130	Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice. Frontiers in Neurology, 2018, 9, 1173.	2.4	6
131	Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function. International Journal of Cardiovascular Imaging, 2018, 34, 701-711.	1.5	13
132	Normal range and usefulness of right ventricular systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. European Heart Journal Cardiovascular Imaging, 2017, 18, 212-223.	1.2	126
133	Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 499-501.	7.1	8
134	Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Cocksackievirus B3-Induced Myocarditis. Stem Cells Translational Medicine, 2017, 6, 1249-1261.	3.3	56
135	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovascular Research, 2017, 113, 906-914.	3.8	20
136	Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. International Journal of Cardiology, 2017, 243, 374-378.	1.7	38
137	Comorbidity “depression” in heart failure “Potential target of patient education and self-management. BMC Cardiovascular Disorders, 2017, 17, 48.	1.7	8
138	Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart, 2017, 4, e000630.	2.3	72
139	Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance. Stem Cells Translational Medicine, 2017, 6, 2135-2145.	3.3	28
140	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Cocksackievirus B3-Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	60
141	The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Failure Reviews, 2017, 22, 743-752.	3.9	40
142	Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Cocksackievirus B3-Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	63
143	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. Current Cardiology Reports, 2017, 19, 70.	2.9	24
144	Right ventricular strain in heart failure: Clinical perspective. Archives of Cardiovascular Diseases, 2017, 110, 562-571.	1.6	42

#	ARTICLE	IF	CITATIONS
145	Inflammation – Cause or Consequence of Heart Failure or Both?. Current Heart Failure Reports, 2017, 14, 251-265.	3.3	324
146	CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis. PLoS ONE, 2017, 12, e0182643.	2.5	28
147	Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?. BMC Cardiovascular Disorders, 2017, 17, 253.	1.7	0
148	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal, 2017, 38, 2936-2943.	2.2	91
149	Low permanent pacemaker rates following Lotus device implantation for transcatheter aortic valve replacement due to modified implantation protocol. Cardiology Journal, 2017, 24, 250-258.	1.2	8
150	Human Endomyocardial Biopsy Specimen-Derived Stromal Cells Modulate Angiotensin II-Induced Cardiac Remodeling. Stem Cells Translational Medicine, 2016, 5, 1707-1718.	3.3	26
151	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications, 2016, 7, 13710.	12.8	190
152	“One Size Does Not Fit All” JACC: Heart Failure, 2016, 4, 460-463.	4.1	9
153	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	2.2	136
154	Transgenic overexpression of adenine nucleotide translocase 1 protects ischemic hearts against oxidative stress. Journal of Molecular Medicine, 2016, 94, 645-653.	3.9	29
155	Giant cell myocarditis: still a conundrum. The need for a worldwide registry. European Journal of Heart Failure, 2016, 18, 1459-1461.	7.1	11
156	Reversible transition from a hypertrophic to a dilated cardiomyopathy. ESC Heart Failure, 2016, 3, 138-142.	3.1	2
157	Clinical Relevance of Left Atrial Strain to Predict Recurrence of Atrial Fibrillation after Catheter Ablation: A Meta-Analysis. Echocardiography, 2016, 33, 724-733.	0.9	40
158	Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice. Journal of Inflammation, 2016, 13, 25.	3.4	21
159	Postprocedural radial artery occlusion rate using a sheathless guiding catheter for left ventricular endomyocardial biopsy performed by transradial approach. BMC Cardiovascular Disorders, 2016, 16, 253.	1.7	15
160	Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clinical Research in Cardiology, 2016, 105, 1011-1020.	3.3	71
161	Update on Myocarditis and Inflammatory Cardiomyopathy: Reemergence of Endomyocardial Biopsy. Revista Espanola De Cardiologia (English Ed), 2016, 69, 178-187.	0.6	76
162	Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. International Journal of Cardiology, 2016, 203, 1061-1066.	1.7	42

#	ARTICLE	IF	CITATIONS
163	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 312-324.	4.1	390
164	A Patient with Quadricuspid Aortic Valve and Ischemic Stroke. Journal of Heart Valve Disease, 2016, 25, 456-458.	0.5	1
165	Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction. ESC Heart Failure, 2015, 2, 121-132.	3.1	30
166	Treatment of Heart Failure in Real-World Clinical Practice: Findings From the <sc>REFLECT</sc> Registry in Patients With <sc>NYHA</sc> Class <sc>II</sc> Symptoms and a Reduced Ejection Fraction. Clinical Cardiology, 2015, 38, 200-207.	1.8	16
167	High-density lipoproteins reduce palmitate-induced cardiomyocyte apoptosis in an AMPK-dependent manner. Biochemical and Biophysical Research Communications, 2015, 466, 272-277.	2.1	13
168	Latent ischaemia as a trigger for a <i>circulus vitiosus</i> of inflammation, fibrosis, and stiffness in HFpEF. European Journal of Heart Failure, 2015, 17, 1210-1212.	7.1	14
169	Cardiac Migration of Endogenous Mesenchymal Stromal Cells in Patients with Inflammatory Cardiomyopathy. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	13
170	Feasibility and safety of left ventricular endomyocardial biopsy via transradial access: Technique and initial experience. Catheterization and Cardiovascular Interventions, 2015, 86, 761-765.	1.7	25
171	Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo- <sc>DHF</sc> trial. European Journal of Heart Failure, 2015, 17, 214-223.	7.1	146
172	High-Density Lipoproteins Reduce Endothelial-to-Mesenchymal Transition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1774-1777.	2.4	58
173	Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a "deeper" look into patients' prognosis. European Heart Journal, 2015, 36, 708-710.	2.2	16
174	Endomyocardial biopsy in Anderson-Fabry disease: The key in uncertain cases. International Journal of Cardiology, 2015, 190, 284-286.	1.7	8
175	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Cocksackievirus B3-induced Myocarditis in Mice. Journal of Infectious Diseases, 2015, 211, 613-622.	4.0	17
176	Diastolic pressure-volume quotient (DPVQ) as a novel echocardiographic index for estimation of LV stiffness in HFpEF. Clinical Research in Cardiology, 2015, 104, 955-963.	3.3	34
177	Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy. Journal of Infectious Diseases, 2015, 212, 1070-1081.	4.0	34
178	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	27.0	1,827
179	Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection. Journal of Clinical Virology, 2015, 63, 1-5.	3.1	29
180	How to perform an endomyocardial biopsy?. Turk Kardiyoloji Dernegi Arsivi, 2015, 43, 572-5.	0.5	16

#	ARTICLE	IF	CITATIONS
181	Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. <i>European Journal of Heart Failure</i> , 2014, 16, 1066-1072.	7.1	32
182	Crosstalk between fibroblasts and inflammatory cells. <i>Cardiovascular Research</i> , 2014, 102, 258-269.	3.8	419
183	Cardiac Fibroblasts Aggravate Viral Myocarditis: Cell Specific Coxsackievirus B3 Replication. <i>Mediators of Inflammation</i> , 2014, 2014, 1-14.	3.0	37
184	Analysis of endomyocardial biopsies in suspected myocarditis – Diagnostic value of left versus right ventricular biopsy. <i>International Journal of Cardiology</i> , 2014, 177, 76-78.	1.7	42
185	New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2014, 11, 436-444.	3.3	78
186	Inhibition of Coagulation Factor Xa Improves Myocardial Function During CVC-Induced Myocarditis. <i>Cardiovascular Therapeutics</i> , 2014, 32, 113-119.	2.5	9
187	A P19 and P19CL6 Cell-Based Complementary Approach to Determine Paracrine Effects in Cardiac Tissue Engineering. <i>Cells Tissues Organs</i> , 2014, 199, 24-36.	2.3	10
188	Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. <i>Clinical Research in Cardiology</i> , 2014, 103, 665-673.	3.3	31
189	Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. <i>Basic Research in Cardiology</i> , 2014, 109, 449.	5.9	55
190	Lack in Treatment Options for Virus-Induced Inflammatory Cardiomyopathy. <i>Circulation Research</i> , 2014, 115, 540-541.	4.5	16
191	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	2.2	304
192	Interleukin-23 Deficiency Leads to Impaired Wound Healing and Adverse Prognosis After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2014, 7, 161-171.	3.9	48
193	Ubiquitin-Like Protein ISG15 (Interferon-Stimulated Gene of 15 kDa) in Host Defense Against Heart Failure in a Mouse Model of Virus-Induced Cardiomyopathy. <i>Circulation</i> , 2014, 130, 1589-1600.	1.6	91
194	Cardiac fibroblasts support cardiac inflammation in heart failure. <i>Basic Research in Cardiology</i> , 2014, 109, 428.	5.9	128
195	Can speckle-tracking imaging improve the reliability of echocardiographic parameters for outcome evaluation in clinical trials?. <i>European Heart Journal</i> , 2014, 35, 605-607.	2.2	12
196	LXR agonism improves TNF- α -induced endothelial dysfunction in the absence of its cholesterol-modulating effects. <i>Atherosclerosis</i> , 2014, 232, 1-9.	0.8	55
197	Ageing and Diastolic Dysfunction: The Interplay of Inflammation and Extracellular Matrix Regulation. , 2014, , 183-198.		0
198	Immune attributes of cardiac-derived adherent proliferating (CAP) cells in cardiac therapy. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2013, 7, 362-370.	2.7	15

#	ARTICLE	IF	CITATIONS
199	Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction â€” Results of the Aldo-DHF trial. International Journal of Cardiology, 2013, 169, 408-417.	1.7	34
200	Protease-Activated Receptor-2 Regulates the Innate Immune Response to Viral Infection in a Cocksackievirus B3â€”Induced Myocarditis. Journal of the American College of Cardiology, 2013, 62, 1737-1745.	2.8	61
201	The utility of speckle tracking imaging in the diagnostic of acute myocarditis, as proven by endomyocardial biopsy. International Journal of Cardiology, 2013, 168, 3023-3024.	1.7	30
202	Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. International Journal of Cardiology, 2013, 168, 4652-4657.	1.7	51
203	Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model. Journal of Surgical Research, 2013, 185, 70-83.	1.6	37
204	A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 263-271.	2.8	2,555
205	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. Circulation: Heart Failure, 2013, 6, 1239-1249.	3.9	241
206	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. Cardiovascular Research, 2013, 99, 111-120.	3.8	113
207	New Echocardiographic Findings Correlate with Intramyocardial Inflammation in Endomyocardial Biopsies of Patients with Acute Myocarditis and Inflammatory Cardiomyopathy. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	54
208	Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 781.	7.4	604
209	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). European Heart Journal, 2013, 34, 512-519.	2.2	472
210	Immunomodulatory Effects of Mesenchymal Stromal Cells Revisited in the Context of Inflammatory Cardiomyopathy. Stem Cells International, 2013, 2013, 1-16.	2.5	12
211	Impact of Atrial Fibrillation on the Accuracy of Oscillometric Blood Pressure Monitoring. Hypertension, 2013, 62, 579-584.	2.7	68
212	Pro-Angiogenic Effect of Endomyocardial Biopsy-Derived Cells for Cardiac Regeneration. Current Tissue Engineering, 2013, 2, 154-159.	0.2	4
213	Protective Function of STAT3 in CVB3-Induced Myocarditis. Cardiology Research and Practice, 2012, 2012, 1-11.	1.1	20
214	Left Ventricular Dysfunction Induced by Nonsevere Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 181-189.	5.6	74
215	Differential Expression of Matrix Metalloproteases in Human Fibroblasts with Different Origins. Biochemistry Research International, 2012, 2012, 1-10.	3.3	90
216	Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2012, 12, 132-147.	1.2	11

#	ARTICLE	IF	CITATIONS
217	Diastolic Heart Failure and LV Dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-2544.	1.6	5
218	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Research in Cardiology, 2012, 107, 308.	5.9	66
219	Diastolic heart failure: What we still don't know. Herz, 2012, 37, 875-879.	1.1	30
220	Heart Failure 2012. Cardiology Research and Practice, 2012, 2012, 1-3.	1.1	15
221	Role of Heart Rate Reduction in the Prevention of Experimental Heart Failure. Hypertension, 2012, 59, 949-957.	2.7	69
222	Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study. International Journal of Cardiology, 2012, 161, 137-142.	1.7	11
223	Mesenchymal Stromal Cells but Not Cardiac Fibroblasts Exert Beneficial Systemic Immunomodulatory Effects in Experimental Myocarditis. PLoS ONE, 2012, 7, e41047.	2.5	48
224	Diastolic Heart Failure and LV Dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-2544.	1.6	9
225	Diastolic heart failure and LV dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-44.	1.6	7
226	Diastolic Tissue Doppler Indexes Correlate With the Degree of Collagen Expression and Cross-Linking in Heart Failure and Normal Ejection Fraction. Journal of the American College of Cardiology, 2011, 57, 977-985.	2.8	273
227	Simultaneous estimation of NT-proBNP on top to mitral flow Doppler echocardiography as an accurate strategy to diagnose diastolic dysfunction in HFNEF. International Journal of Cardiology, 2011, 149, 23-29.	1.7	26
228	Cardiac Cell Therapies: The Next Generation. Cardiovascular Therapeutics, 2011, 29, 2-16.	2.5	18
229	Human Cardiac-Derived Adherent Proliferating Cells Reduce Murine Acute Coxsackievirus B3-Induced Myocarditis. PLoS ONE, 2011, 6, e28513.	2.5	44
230	Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy. Current Pharmaceutical Design, 2011, 17, 3295-3307.	1.9	14
231	Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. Journal of Molecular Medicine, 2011, 89, 151-160.	3.9	36
232	Transcatheter Implantation of the MONARC Coronary Sinus Device for Mitral Regurgitation. JACC: Cardiovascular Interventions, 2011, 4, 115-122.	2.9	108
233	Acute Exposure to Doxorubicin Results in Increased Cardiac P-glycoprotein Expression. Journal of Pharmaceutical Sciences, 2011, 100, 3951-3958.	3.3	15
234	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. Circulation, 2011, 124, 2082-2093.	1.6	81

#	ARTICLE	IF	CITATIONS
235	TRIF Is a Critical Survival Factor in Viral Cardiomyopathy. <i>Journal of Immunology</i> , 2011, 186, 2561-2570.	0.8	71
236	Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. <i>Heart</i> , 2011, 97, 709-714.	2.9	61
237	Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 44-52.	3.9	493
238	Increased Left Ventricular Stiffness Impairs Exercise Capacity in Patients with Heart Failure Symptoms Despite Normal Left Ventricular Ejection Fraction. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-10.	1.1	25
239	8 Kallikrein-kinin system in the heart. , 2011, , .		3
240	Endomyocardial biopsy derived adherent proliferating cellsâ€”A potential cell source for cardiac tissue engineering. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 564-575.	2.6	23
241	High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders. <i>Current Pharmaceutical Design</i> , 2010, 16, 1504-1516.	1.9	43
242	High-Density Lipoprotein-Raising Strategies: Update 2010. <i>Current Pharmaceutical Design</i> , 2010, 16, 1517-1530.	1.9	14
243	Kinins in cardiac inflammation and regeneration: Insights from ischemic and diabetic cardiomyopathy. <i>Neuropeptides</i> , 2010, 44, 119-125.	2.2	16
244	Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis â€” ongoing inflammation and an imbalance of the matrix degrading system. <i>European Journal of Pharmacology</i> , 2010, 630, 145-151.	3.5	31
245	Quantification of Circulating Endothelial Progenitor Cells Using the Modified ISHAGE Protocol. <i>PLoS ONE</i> , 2010, 5, e13790.	2.5	120
246	First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. <i>Integrated Blood Pressure Control</i> , 2010, 3, 163.	1.2	4
247	A Common <i>MLP</i> (Muscle LIM Protein) Variant Is Associated With Cardiomyopathy. <i>Circulation Research</i> , 2010, 106, 695-704.	4.5	90
248	Circulating Rather Than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2010, 3, 286-293.	3.9	77
249	Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 936-945.	4.0	63
250	Single-beat estimation of the left ventricular end-diastolic pressure-volume relationship in patients with heart failure. <i>Heart</i> , 2010, 96, 213-219.	2.9	36
251	Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H2024-H2031.	3.2	43
252	Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure-volume loop analysis. <i>European Journal of Echocardiography</i> , 2010, 11, 743-751.	2.3	80

#	ARTICLE	IF	CITATIONS
253	Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. <i>International Immunopharmacology</i> , 2010, 10, 207-212.	3.8	18
254	Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 922-930.	1.7	153
255	Immunomodulation and matrix metalloproteinases in viral myocarditis. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 468-473.	1.9	48
256	Impact of HDL on adipose tissue metabolism and adiponectin expression. <i>Atherosclerosis</i> , 2010, 210, 438-444.	0.8	71
257	Activation of mitochondrial energy metabolism protects against cardiac failure. <i>Aging</i> , 2010, 2, 843-853.	3.1	53
258	Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice. <i>Cancer Research</i> , 2009, 69, 695-699.	0.9	165
259	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. <i>Circulation</i> , 2009, 120, 2358-2366.	1.6	67
260	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 119-129.	7.1	281
261	Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. <i>European Heart Journal</i> , 2009, 30, 3027-3036.	2.2	100
262	Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy. <i>Diabetes</i> , 2009, 58, 1373-1381.	0.6	102
263	Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor. <i>Hypertension</i> , 2009, 53, 682-687.	2.7	76
264	Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. <i>Circulation</i> , 2009, 119, 1241-1252.	1.6	200
265	Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures. <i>Circulation</i> , 2009, 120, 810-820.	1.6	111
266	Truncation of Titin's Elastic PEVK Region Leads to Cardiomyopathy With Diastolic Dysfunction. <i>Circulation Research</i> , 2009, 105, 557-564.	4.5	105
267	Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. <i>Basic Research in Cardiology</i> , 2009, 104, 499-509.	5.9	63
268	Heart Failure with Normal Ejection Fraction. <i>Herz</i> , 2009, 34, 89-96.	1.1	27
269	Cardiac Deletion of the Coxsackievirus-Adenovirus Receptor Abolishes Coxsackievirus B3 Infection and Prevents Myocarditis In Vivo. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1219-1226.	2.8	103
270	The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. <i>Cytotherapy</i> , 2009, 11, 427-434.	0.7	116

#	ARTICLE	IF	CITATIONS
271	Renin inhibitors, clinical experience. <i>Journal of Molecular Medicine</i> , 2008, 86, 691-695.	3.9	19
272	Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. <i>Journal of Molecular Medicine</i> , 2008, 86, 987-997.	3.9	73
273	Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. <i>Diabetologia</i> , 2008, 51, 2325-2332.	6.3	29
274	Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. <i>Basic Research in Cardiology</i> , 2008, 103, 319-327.	5.9	165
275	The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. <i>European Journal of Pharmacology</i> , 2008, 590, 276-280.	3.5	55
276	New perspective on the tissue kallikrein-kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration. <i>International Immunopharmacology</i> , 2008, 8, 148-154.	3.8	26
277	The cardiovascular influence of interleukin-1 β on the expression of bradykinin B1 and B2 receptors. <i>International Immunopharmacology</i> , 2008, 8, 222-230.	3.8	8
278	Viral myocarditis and coagulopathy: Increased tissue factor expression and plasma thrombogenicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 118-126.	1.9	43
279	Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice This article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 353-357.	1.4	6
280	Human Parvovirus B19 NS1 Protein Modulates Inflammatory Signaling by Activation of STAT3/PIAS3 in Human Endothelial Cells. <i>Journal of Virology</i> , 2008, 82, 7942-7952.	3.4	80
281	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. <i>Biological Chemistry</i> , 2008, 389, 713-718.	2.5	22
282	Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction. <i>Circulation</i> , 2008, 117, 2051-2060.	1.6	403
283	Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach. <i>Circulation</i> , 2008, 118, 1722-1728.	1.6	223
284	Development of diabetic cardiomyopathy and the kallikrein-kinin system – new insights from B1 and B2 receptor signaling. <i>Biological Chemistry</i> , 2008, 389, 707-711.	2.5	12
285	Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice. <i>Journal of Immunology</i> , 2008, 180, 6954-6961.	0.8	112
286	Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. <i>European Journal of Heart Failure</i> , 2008, 10, 233-243.	7.1	136
287	Up-regulation of PPAR β in myocardial infarction. <i>European Journal of Heart Failure</i> , 2008, 10, 30-38.	7.1	25
288	Angiotensin II Type 2 Receptor Stimulation. <i>Circulation</i> , 2008, 118, 2523-2532.	1.6	250

#	ARTICLE	IF	CITATIONS
289	Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model. <i>Biological Chemistry</i> , 2008, 389, 719-23.	2.5	11
290	Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy. <i>Circulation</i> , 2008, 117, 1563-1573.	1.6	103
291	Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure. <i>Hypertension</i> , 2008, 52, 1068-1075.	2.7	91
292	Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy. <i>Diabetes</i> , 2007, 56, 1834-1841.	0.6	121
293	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. <i>European Heart Journal</i> , 2007, 28, 821-828.	2.2	86
294	Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy: The Role of Angiotensin Type 1 Receptor Antagonism. <i>Diabetes</i> , 2007, 56, 641-646.	0.6	244
295	The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy. <i>Cancer Research</i> , 2007, 67, 10428-10435.	0.9	85
296	Accelerated Mitochondrial Adenosine Diphosphate/Adenosine Triphosphate Transport Improves Hypertension-Induced Heart Disease. <i>Circulation</i> , 2007, 115, 333-344.	1.6	60
297	The role of the renal kallikrein-kinin system in diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 22-26.	2.0	41
298	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 2539-2550.	2.2	2,302
299	Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Diastolic Function in Heart Failure With Normal Ejection Fraction. <i>Circulation</i> , 2007, 116, 637-647.	1.6	917
300	Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. <i>European Journal of Pharmacology</i> , 2007, 554, 60-68.	3.5	32
301	Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. <i>European Journal of Pharmacology</i> , 2007, 554, 40-45.	3.5	25
302	Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. <i>European Journal of Pharmacology</i> , 2007, 569, 204-211.	3.5	48
303	Role of Gender in Heart Failure with Normal Left Ventricular Ejection Fraction. <i>Progress in Cardiovascular Diseases</i> , 2007, 49, 241-251.	3.1	121
304	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. <i>Basic Research in Cardiology</i> , 2007, 102, 500-507.	5.9	180
305	Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 22-29.	2.0	29
306	Coronary vasospasm-induced acute diastolic dysfunction in a patient with Raynaud's phenomenon. <i>Clinical Research in Cardiology</i> , 2006, 95, 344-348.	3.3	13

#	ARTICLE	IF	CITATIONS
307	Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. <i>European Journal of Pharmacology</i> , 2006, 550, 143-148.	3.5	23
308	Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. <i>Regenerative Medicine</i> , 2006, 1, 235-254.	1.7	25
309	Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2006, 8, 115-121.	7.1	83
310	Angiotensin AT ₂ Receptor Deficiency After Myocardial Infarction: Its Effects on Cardiac Function and Fibrosis Depend on the Stimulus. <i>Cell Biochemistry and Biophysics</i> , 2005, 43, 045-052.	1.8	11
311	Protection against oxidative stress in diabetic rats: Role of angiotensin AT ₁ receptor and beta 1-adrenoceptor antagonism. <i>European Journal of Pharmacology</i> , 2005, 520, 179-187.	3.5	30
312	Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1 β and MMP-8 expression and a modulated immune response. <i>European Journal of Heart Failure</i> , 2005, 7, 444-452.	7.1	71
313	Protective Role of Angiopoietin-1 in Endotoxic Shock. <i>Circulation</i> , 2005, 111, 97-105.	1.6	189
314	Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. <i>FASEB Journal</i> , 2005, 19, 2057-2059.	0.5	114
315	The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. <i>European Heart Journal</i> , 2005, 26, 2277-2284.	2.2	258
316	Elevated NT-ProBNP Levels in Patients With Increased Left Ventricular Filling Pressure During Exercise Despite Preserved Systolic Function. <i>Journal of Cardiac Failure</i> , 2005, 11, S28-S33.	1.7	34
317	Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. <i>FASEB Journal</i> , 2004, 18, 828-835.	0.5	97
318	Improvement of defective sarcoplasmic reticulum Ca ²⁺ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. <i>FASEB Journal</i> , 2004, 18, 1967-1969.	0.5	27
319	The bradykinin B ₁ receptor contributes to the cardioprotective effects of AT ₁ blockade after experimental myocardial infarction. <i>Cardiovascular Research</i> , 2004, 61, 559-569.	3.8	45
320	Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. <i>European Journal of Pharmacology</i> , 2004, 491, 173-179.	3.5	16
321	Angiotensin deficiency in mice leads to dilated cardiomyopathy. <i>European Journal of Pharmacology</i> , 2004, 493, 161-165.	3.5	17
322	Fibrosis rather than blood pressure determines cardiac BNP expression in mice. <i>Regulatory Peptides</i> , 2003, 116, 95-100.	1.9	26
323	Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. <i>International Immunopharmacology</i> , 2003, 3, 335-344.	3.8	28
324	Cardiac kinin level in experimental diabetes mellitus: role of kininases. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H418-H423.	3.2	19

#	ARTICLE	IF	CITATIONS
325	Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovascular Research, 2002, 56, 235-247.	3.8	102
326	AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB Journal, 2002, 16, 1237-1241.	0.5	23
327	Multiple Interactions Between the Renin-Angiotensin and the Kallikrein-Kinin Systems: Role of ACE Inhibition and AT1 Receptor Blockade. Journal of Cardiovascular Pharmacology, 2002, 39, 478-487.	1.9	105
328	Transgenic overexpression of the sarcoplasmic reticulum Ca ²⁺ ATPase improves reticular Ca ²⁺ handling in normal and diabetic rat hearts. FASEB Journal, 2002, 16, 1657-1659.	0.5	88
329	Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. International Immunopharmacology, 2002, 2, 1823-1832.	3.8	40
330	Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. Journal of Hypertension, 2000, 18, 223-228.	0.5	47
331	Upregulation of bradykinin B1-receptor expression after myocardial infarction. British Journal of Pharmacology, 2000, 129, 1537-1538.	5.4	57
332	Increased kallikrein expression protects against cardiac ischemia. FASEB Journal, 2000, 14, 1861-1863.	0.5	37
333	Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB Journal, 2000, 14, 1858-1860.	0.5	112
334	Upregulation of the cardiac bradykinin B2 receptors after myocardial infarction. Immunopharmacology, 1999, 44, 111-117.	2.0	15
335	Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology, 1999, 44, 35-42.	2.0	35
336	Renal expression of two rat kallikrein genes under diabetic conditions. Journal of Hypertension, 1997, 15, 1711-1714.	0.5	8
337	Bradykinin and Cardiac Protection. Advances in Experimental Medicine and Biology, 1997, 432, 159-172.	1.6	7
338	Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology, 1996, 33, 344-348.	2.0	13
339	Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats. Brain Research, 1995, 690, 15-24.	2.2	16
340	Further localization of cardiovascular and behavioral actions of substance P in the rat brain. Brain Research, 1994, 668, 100-106.	2.2	13
341	Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors. Brain Research, 1993, 625, 75-83.	2.2	23
342	Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK ₁ and NK ₂ receptors in the rat. British Journal of Pharmacology, 1992, 107, 750-755.	5.4	38

#	ARTICLE	IF	CITATIONS
343	Localization of the substance P-induced cardiovascular responses in the rat hypothalamus. Brain Research, 1991, 558, 123-126.	2.2	35
344	Myokarditis: Meist mit Defektheilung. , 0, , .		0